Sanofi
SNYNASDAQHealthcare● Active
$45.02
+$0.64(+1.44%)
Market Cap$108.4B
P/E Ratio—
52W High$52.68
52W Low$42.28
Sanofi (SNY) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SNY · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 23, 2026EPS Actual
$1.10
Est. $1.06 · +3.8%
Revenue
$12.94B
Est. $12.68B · +2.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 23, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 3-Quarter EPS Beat Streak
SNY reports quarterly as a NASDAQ-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.00
Rev. $0.01B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.00
Rev. Est.$0.01B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 30, 2026 | $1.20 | — | — | — | $12.87B | — |
| ▲ Q2 FY2026 | Apr 23, 2026 | $1.06 | $1.10 | +3.8% | $12.94B | $12.68B | +2.1% |
| ▲ Q1 FY2026 | Jan 29, 2026 | $0.84 | $0.89 | +6.0% | $14.34B | $11.71B | +22.4% |
| ▲ Q4 FY2025 | Oct 24, 2025 | $1.60 | $1.70 | +6.3% | $15.43B | $11.11B | +38.9% |
| ▼ Q3 FY2025 | Jul 31, 2025 | $0.96 | $0.90 | -6.3% | $12.64B | $12.36B | +2.3% |
| ▲ Q2 FY2025 | Apr 24, 2025 | $0.90 | $0.94 | +4.4% | $11.63B | $10.00B | +16.3% |
| ▼ Q1 FY2025 | Jan 30, 2025 | $0.71 | $0.70 | -1.4% | $7.90B | $9.51B | -16.9% |
| ▲ Q4 FY2024 | Oct 25, 2024 | $1.35 | $1.57 | +16.3% | $15.53B | $13.94B | +11.4% |
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
$1.20
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 23, 2026Beat
EPS Actual
$1.10
EPS Est.
$1.06
EPS Surpr.
+3.8%
Revenue
$12.94B
Q1 FY2026
Jan 29, 2026Beat
EPS Actual
$0.89
EPS Est.
$0.84
EPS Surpr.
+6.0%
Revenue
$14.34B
Q4 FY2025
Oct 24, 2025Beat
EPS Actual
$1.70
EPS Est.
$1.60
EPS Surpr.
+6.3%
Revenue
$15.43B
Q3 FY2025
Jul 31, 2025Miss
EPS Actual
$0.90
EPS Est.
$0.96
EPS Surpr.
-6.3%
Revenue
$12.64B
Q2 FY2025
Apr 24, 2025Beat
EPS Actual
$0.94
EPS Est.
$0.90
EPS Surpr.
+4.4%
Revenue
$11.63B
Q1 FY2025
Jan 30, 2025Miss
EPS Actual
$0.70
EPS Est.
$0.71
EPS Surpr.
-1.4%
Revenue
$7.90B
Q4 FY2024
Oct 25, 2024Beat
EPS Actual
$1.57
EPS Est.
$1.35
EPS Surpr.
+16.3%
Revenue
$15.53B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2026 | $1.28 | $1.48 | $1.58 | 3 |
| Q2 FY2026 | $0.88 | $1.04 | $1.59 | 4 |
| Q1 FY2026 | $0.87 | $0.90 | $0.92 | 4 |
| Q4 FY2025 | $0.69 | $0.72 | $0.74 | 4 |
| Q3 FY2025 | $1.26 | $1.37 | $1.49 | 3 |
| Q2 FY2025 | $0.79 | $0.82 | $0.83 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2026 | $12.9B | $13.4B | $14.2B | 4 |
| Q2 FY2026 | $10.2B | $10.8B | $11.7B | 4 |
| Q1 FY2026 | $9.8B | $10.2B | $10.8B | 4 |
| Q4 FY2025 | $11.0B | $11.5B | $11.9B | 5 |
| Q3 FY2025 | $12.2B | $12.3B | $12.7B | 5 |
| Q2 FY2025 | $9.3B | $9.5B | $10.0B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 23, 2026 | +3.8% | $46.90 | $47.53 | +1.34% |
| ▲ Q1 FY2026 | Jan 29, 2026 | +6.0% | $45.77 | $46.20 | +0.94% |
| ▲ Q4 FY2025 | Oct 24, 2025 | +6.3% | $49.52 | $51.64 | +4.28% |
| ▼ Q3 FY2025 | Jul 31, 2025 | -6.3% | $49.25 | $45.64 | -7.33% |
| ▲ Q2 FY2025 | Apr 24, 2025 | +4.4% | $53.02 | $53.54 | +0.98% |
| ▼ Q1 FY2025 | Jan 30, 2025 | -1.4% | $52.15 | $54.15 | +3.84% |
| ▲ Q4 FY2024 | Oct 25, 2024 | +16.3% | $52.05 | $54.34 | +4.40% |
| ▲ Q3 FY2024 | Jul 25, 2024 | +8.1% | $51.20 | $53.10 | +3.71% |
Q2 FY2026+1.34%
Report Date
Apr 23, 2026
EPS Beat/Miss
+3.8%
Price Before
$46.90
Price After
$47.53
Q1 FY2026+0.94%
Report Date
Jan 29, 2026
EPS Beat/Miss
+6.0%
Price Before
$45.77
Price After
$46.20
Q4 FY2025+4.28%
Report Date
Oct 24, 2025
EPS Beat/Miss
+6.3%
Price Before
$49.52
Price After
$51.64
Q3 FY2025-7.33%
Report Date
Jul 31, 2025
EPS Beat/Miss
-6.3%
Price Before
$49.25
Price After
$45.64
Q2 FY2025+0.98%
Report Date
Apr 24, 2025
EPS Beat/Miss
+4.4%
Price Before
$53.02
Price After
$53.54
Q1 FY2025+3.84%
Report Date
Jan 30, 2025
EPS Beat/Miss
-1.4%
Price Before
$52.15
Price After
$54.15
Q4 FY2024+4.40%
Report Date
Oct 25, 2024
EPS Beat/Miss
+16.3%
Price Before
$52.05
Price After
$54.34
Q3 FY2024+3.71%
Report Date
Jul 25, 2024
EPS Beat/Miss
+8.1%
Price Before
$51.20
Price After
$53.10
Avg Beat Reaction+2.61%
Avg Miss Reaction-1.75%
Beat Rate6 / 8 quarters
Largest Move-7.33% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SNY ends December
Sanofi (SNY) most recently reported earnings on April 23, 2026 for Q2 FY2026, posting EPS of $1.10 — beating the analyst consensus of $1.06 by +3.8%. SNY has beaten EPS estimates for 3 consecutive quarters. The next SNY earnings date is expected around September 1, 2026.
Each quarter, investors track SNY earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SNY revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SNY's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SNY earnings · 5 questionsSanofi's next earnings report is expected around September 1, 2026. SNY typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SNY historically reports after market close (AMC).
SNY earnings datewhen is SNY earningsSNY next earnings datewhen does SNY report earningsSNY earnings calendar
▸ Source: FMP · Sanofi SEC filings · US GAAP · Sanofi SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026